Concepts (96)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Monoamine Oxidase Inhibitors | 3 | 2020 | 28 | 0.450 |
Why?
|
| Receptors, Dopamine D2 | 3 | 2020 | 83 | 0.380 |
Why?
|
| Tetrahydroisoquinolines | 2 | 2021 | 22 | 0.290 |
Why?
|
| Monoamine Oxidase | 2 | 2020 | 37 | 0.290 |
Why?
|
| Flavonoids | 2 | 2020 | 100 | 0.270 |
Why?
|
| Antipsychotic Agents | 3 | 2020 | 80 | 0.270 |
Why?
|
| Drug Design | 3 | 2021 | 186 | 0.250 |
Why?
|
| Antineoplastic Agents | 3 | 2021 | 1019 | 0.230 |
Why?
|
| Structure-Activity Relationship | 7 | 2020 | 506 | 0.200 |
Why?
|
| Molecular Structure | 6 | 2021 | 570 | 0.190 |
Why?
|
| Haloperidol | 2 | 2012 | 36 | 0.180 |
Why?
|
| Apomorphine | 1 | 2020 | 13 | 0.170 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2021 | 62 | 0.160 |
Why?
|
| Piperazines | 1 | 2020 | 120 | 0.160 |
Why?
|
| Pyridines | 1 | 2020 | 139 | 0.160 |
Why?
|
| Neovascularization, Pathologic | 1 | 2021 | 139 | 0.160 |
Why?
|
| Cell Proliferation | 3 | 2021 | 1455 | 0.150 |
Why?
|
| Behavior, Animal | 1 | 2020 | 373 | 0.140 |
Why?
|
| Psoralea | 1 | 2017 | 2 | 0.130 |
Why?
|
| Chalcones | 1 | 2017 | 17 | 0.130 |
Why?
|
| Genistein | 1 | 2017 | 45 | 0.130 |
Why?
|
| Benzoquinones | 1 | 2017 | 47 | 0.130 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2016 | 27 | 0.120 |
Why?
|
| Ibuprofen | 1 | 2016 | 34 | 0.120 |
Why?
|
| Receptor, Serotonin, 5-HT1A | 2 | 2014 | 17 | 0.120 |
Why?
|
| Microtubules | 1 | 2016 | 121 | 0.120 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2016 | 146 | 0.110 |
Why?
|
| Antiviral Agents | 1 | 2017 | 195 | 0.110 |
Why?
|
| Receptors, Dopamine D4 | 1 | 2014 | 16 | 0.110 |
Why?
|
| Acrylamides | 1 | 2014 | 14 | 0.110 |
Why?
|
| Dopamine Antagonists | 1 | 2014 | 48 | 0.110 |
Why?
|
| Quinolines | 2 | 2013 | 78 | 0.100 |
Why?
|
| Quinolinium Compounds | 1 | 2013 | 9 | 0.100 |
Why?
|
| Cryptococcus | 1 | 2013 | 10 | 0.100 |
Why?
|
| Plant Extracts | 1 | 2017 | 302 | 0.100 |
Why?
|
| Sulfhydryl Compounds | 1 | 2013 | 51 | 0.100 |
Why?
|
| Sulfonamides | 1 | 2014 | 91 | 0.100 |
Why?
|
| Pyrimidines | 1 | 2014 | 139 | 0.100 |
Why?
|
| Depression | 1 | 2020 | 863 | 0.100 |
Why?
|
| Indoles | 1 | 2014 | 187 | 0.090 |
Why?
|
| Quantitative Structure-Activity Relationship | 1 | 2013 | 110 | 0.090 |
Why?
|
| Serotonin Plasma Membrane Transport Proteins | 1 | 2012 | 15 | 0.090 |
Why?
|
| Benzothiazoles | 1 | 2012 | 26 | 0.090 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2014 | 187 | 0.090 |
Why?
|
| Azepines | 1 | 2012 | 22 | 0.090 |
Why?
|
| Antifungal Agents | 1 | 2013 | 169 | 0.090 |
Why?
|
| Antidepressive Agents | 1 | 2012 | 65 | 0.090 |
Why?
|
| Cell Line, Tumor | 4 | 2020 | 2676 | 0.090 |
Why?
|
| Prostatic Neoplasms | 1 | 2020 | 1092 | 0.080 |
Why?
|
| Inhibitory Concentration 50 | 2 | 2020 | 99 | 0.080 |
Why?
|
| Fungi | 1 | 2010 | 106 | 0.080 |
Why?
|
| Cell Survival | 3 | 2020 | 945 | 0.070 |
Why?
|
| Kinetics | 2 | 2020 | 695 | 0.060 |
Why?
|
| Animals | 7 | 2020 | 16992 | 0.060 |
Why?
|
| Humans | 10 | 2021 | 43102 | 0.060 |
Why?
|
| Binding, Competitive | 2 | 2017 | 109 | 0.060 |
Why?
|
| Ligands | 2 | 2016 | 388 | 0.050 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2021 | 157 | 0.040 |
Why?
|
| Mice | 3 | 2020 | 6644 | 0.040 |
Why?
|
| Crystallography, X-Ray | 1 | 2020 | 280 | 0.040 |
Why?
|
| Catalytic Domain | 1 | 2020 | 118 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2020 | 1124 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2021 | 1621 | 0.030 |
Why?
|
| Dopamine Agents | 1 | 2016 | 28 | 0.030 |
Why?
|
| Cell Movement | 1 | 2020 | 655 | 0.030 |
Why?
|
| Tubulin | 1 | 2016 | 96 | 0.030 |
Why?
|
| Cyclooxygenase 2 | 1 | 2016 | 107 | 0.030 |
Why?
|
| Cell Cycle | 1 | 2016 | 346 | 0.030 |
Why?
|
| Receptor, Serotonin, 5-HT2B | 1 | 2014 | 7 | 0.030 |
Why?
|
| Cricetulus | 1 | 2014 | 82 | 0.030 |
Why?
|
| Interleukin-1alpha | 1 | 2014 | 18 | 0.030 |
Why?
|
| CHO Cells | 1 | 2014 | 123 | 0.030 |
Why?
|
| Cricetinae | 1 | 2014 | 241 | 0.030 |
Why?
|
| Indole Alkaloids | 1 | 2013 | 14 | 0.030 |
Why?
|
| Basidiomycota | 1 | 2013 | 12 | 0.030 |
Why?
|
| Least-Squares Analysis | 1 | 2013 | 45 | 0.030 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2014 | 128 | 0.030 |
Why?
|
| Vero Cells | 1 | 2013 | 112 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2014 | 165 | 0.020 |
Why?
|
| Lipopolysaccharides | 1 | 2014 | 239 | 0.020 |
Why?
|
| Butyrophenones | 1 | 2011 | 8 | 0.020 |
Why?
|
| Microglia | 1 | 2014 | 208 | 0.020 |
Why?
|
| Receptors, Serotonin | 1 | 2011 | 23 | 0.020 |
Why?
|
| Receptors, Dopamine | 1 | 2011 | 30 | 0.020 |
Why?
|
| Substrate Specificity | 1 | 2012 | 219 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2010 | 11 | 0.020 |
Why?
|
| Nitric Oxide | 1 | 2014 | 386 | 0.020 |
Why?
|
| Male | 2 | 2020 | 23409 | 0.020 |
Why?
|
| Cell Line | 1 | 2014 | 1410 | 0.020 |
Why?
|
| Candidiasis | 1 | 2010 | 89 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2013 | 1081 | 0.020 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2010 | 245 | 0.020 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2010 | 301 | 0.020 |
Why?
|
| Blood-Brain Barrier | 1 | 2010 | 173 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2010 | 465 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2010 | 1596 | 0.010 |
Why?
|